High SLC30A2 expression was significantly correlated with poor OS, FPS, and PPS in in all of GC patients indicating that these genes play an oncogenic role in GC and are markers for improved GC survival and prognostic accuracy. This evidence concerns the gene SLC30A2 and gastric cancer.